Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo…
- Results Underscore Need for Continued Research and Diverse Treatment PipelineCHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed…
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase…
Testing of the GMR-001 Hypercar entered a new phase last week at Circuit Magny-Cours in France where Genesis Magma Racing…
HONG KONG, Nov. 12, 2025 /PRNewswire/ -- CoinW, a leading global crypto asset trading platform, today announced the launch of…
November 08, 2025 17:13 ET | Source: Intellia Therapeutics, Inc. Deep, stable and durable reductions in kallikrein observed Among 32 patients…
DALLAS, Nov. 4, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc. announced today positive long-term safety results from its EXTEND study, a…
Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic…
Dubai, UAE, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM) continues to advance steadily through its development roadmap, completing its…
Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial…